Colchicine for the secondary prevention of cardiovascular events

作者：Fahim Ebrahimi, Ramin Ebrahimi, Maximilian Beer, Christof Schönenberger, Hannah Ewald, Matthias Briel, Perrine Janiaud, Julian Hirt, Lars G. Hemkens · 发表于：Cochrane Database of Systematic Reviews · 年份：2025 · DOI：10.1002/14651858.cd014808.pub2 · 被引用次数：4 · 研究领域：Inflammasome and immune disorders、Pericarditis and Cardiac Tamponade、Gout, Hyperuricemia, Uric Acid

RATIONALE: People with cardiovascular disease are at risk of recurrent major adverse cardiovascular events, and chronic low-grade inflammation may be a major underlying factor. Treatment with low-dose colchicine has been proposed for the secondary prevention of cardiovascular events in individuals at high cardiovascular risk. A previous Cochrane review showed considerable uncertainty regarding the benefits and harms of this approach. OBJECTIVES: To evaluate the benefits and harms of low-dose colchicine in the prevention of cardiovascular events in adults with a history of stable CVD or following myocardial infarction or stroke. SEARCH METHODS: We conducted a comprehensive search of the literature until February 2025 using Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, the drugs@FDA database, references of key papers, and references of included studies. ELIGIBILITY CRITERIA: Randomised controlled trials (RCTs) comparing the use of low-dose colchicine for a minimum of six months versus any control intervention in patients of any age with cardiovascular disease (i.e. history of stable cardiovascular disease, previous myocardial infarction or stroke). OUTCOMES: Our critical outcomes were all-cause mortality, myocardial infarction, and serious adverse events. Our important outcomes were cardiovascular mortality, stroke, all-cause hospitalisations, coronary revascularisation (percutaneous coronary intervention (PCI)/angioplasty or coronary artery bypass ...